Inactive Instrument

News Oasmia Pharmaceutical AB NORDIC GROWTH MARKET

Equities

OASM

SE0000722365

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Notice of Annual General Meeting in Vivesto AB	Apr. 23	AQ
Transcript : Vivesto AB - Special Call	Mar. 26
Vivesto to hold live-streamed Paccal Vet R&D Update on March 26	Mar. 19	AQ
Vivesto doses first patient in its clinical Paccal Vet trial	Mar. 07	AQ
Vivesto AB Doses First Patient in its Clinical Paccal Vet Trial	Mar. 07	CI
Vivesto AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Vivesto's international patent application for XR-18 receives positive decision	Jan. 30	AQ
Vivesto's International Patent Application for XR-18 Receives Positive Decision	Jan. 30	CI
Vivesto Gains on Receipt of US Approval for Pilot Clinical Trial of Drug Candidate Paccal Vet	Dec. 28	MT
Vivesto’s US clinical Paccal Vet trial receives approval to start patient recruitment	Dec. 28	AQ
Vivesto AB's US Clinical Paccal Vet Trial Receives Approval to Start Patient Recruitment	Dec. 28	CI
Vivesto’s Paccal Vet granted FDA MUMS designation	Dec. 22	AQ
Vivesto makes impairment charge following withdrawal of European market authorizations for Apealea	Dec. 22	AQ
Vivesto AB Reports Positive Preclinical Data Supporting Continued Development of Cantrixil	Dec. 19	CI
Vivesto reports positive preclinical data supporting continued development of Cantrixil	Dec. 19	AQ
Nomination Committee appointed for the 2024 Annual General Meeting in Vivesto	Nov. 23	AQ
Vivesto AB Announces Composition of Nomination Committee	Nov. 23	CI
Vivesto Abandons Apealea Partnership with Elevar Therapeutics	Nov. 23	MT
Vivesto and Elevar sign agreement ending Apealea® partnership	Nov. 23	AQ
Vivesto AB and Elevar Therapeutics Inc. Sign Agreement Ending Apealea®? Partnership	Nov. 23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Oasmia Pharmaceutical AB NORDIC GROWTH MARKET

Equities

OASM

SE0000722365

Summary

Filters